GLP-1 treatment late in life extends lifespan in animal model
Peer-Reviewed Publication
Updates every hour. Last Updated: 24-Oct-2026 12:17 ET (24-Oct-2026 16:17 GMT/UTC)
An NIH-funded study has shown that the GLP-1 drug semaglutide extended lifespan in older, healthy mice by tempering the detrimental effects of aging. Researchers directly compared the effects of the treatment to those of reduced food intake, finding that the drug mimicked the anti-aging benefits of calorie restriction, conferring even greater benefits in some areas.
A new Saint Louis University study of nearly a decade of health records finds that the recent rise in autism spectrum disorder (ASD) diagnoses is being driven largely by girls and women, who are being identified at significantly higher rates than in years past, often years later than boys and men.
Hematopoietic loss of chromosome Y (LOY) has emerged as one of the most prevalent somatic genomic alterations in aging males, yet its biological significance extends far beyond a mere marker of aging. This comprehensive review synthesizes current understanding of LOY, from its molecular origins in mitotic chromosome mis-segregation to its far-reaching clinical implications. Advances in detection technologies, including single-cell sequencing and bulk genomic approaches, have enabled robust identification of LOY across population scales. The review examines how inherited genetic variation, environmental exposures, and aging collectively contribute to LOY pathogenesis. Large-scale genome-wide association studies have revealed compelling epidemiological links between hematopoietic LOY and cardiovascular disease, neurodegenerative conditions, immune disorders, and cancer. Mechanistically, LOY drives altered gene expression, immune dysregulation, and clonal expansion of affected hematopoietic cells. Critically, CRISPR-based mouse and cellular models have recapitulated key disease phenotypes, establishing LOY as a functionally consequential form of somatic mosaicism with profound implications for disease susceptibility and male health disparities.
CAMBRIDGE, Mass., September 2 - Insilico Medicine (“Insilico”; HKEX: 3696), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced the release of a series of frontier specialist models for chemistry and biology, trained through its MMAI Gym for Science framework. Across chemistry and biology, the models demonstrate state-of-the-art (SOTA) performance on more than 50 benchmark tasks.